Treatment patterns and persistence rates with anti‐vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real‐world study
Authors:
Open Access
- 19 November 2021
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 39 (4) , e14746
Abstract
Introduction: Anti‐vascular endothelial growth factors (anti‐VEGFs) are considered standard of care therapy for diabetic macular oedema (DME). This study examined treatment patterns and outcomes in patients with DME treated with anti‐VEGF therapy.Methods: Using anonymized electronic medical record data collected from three UK sites, this retrospective cohort study assessed rates of anti‐VEGF intravitreal injections in adults with treatment‐naïve DME who received their first treatment between 1 September 2010 and 31 July 2018. The proportion of patients with at least one interval of at least 12 weeks between injections; the distribution of injection intervals; the discontinuation rates; and the number of anti‐VEGF injection‐, injection‐free‐ and total visits were assessed during the first and second years of treatment.Results: Overall, 1606 patient eyes with DME were included, with no minimum follow‐up. During the first and second year of treatment, 63.2% and 73.1% of eyes had at least one anti‐VEGF injection interval of at least 12 weeks, respectively. In the first and second years of treatment, the mean (standard deviation) numbers of injections were 7.7 (1.9) and 5.6 (2.2), with 14.2 (5.7) and 13.4 (6.4) total clinic visits, and 6.6 (5.0) and 7.8 (5.8) injection‐free visits, respectively. In total, 27.8% of patient eyes discontinued treatment during the first 2 years.Conclusions: The high number of clinic visits and high discontinuation rates demonstrate a significant unmet need for a treatment to enable sustainable extended injection intervals, while maintaining visual acuity. This could improve patient adherence and health‐related quality of life for patients with DME.Keywords
This publication has 26 references indexed in Scilit:
- Comorbidity and Health Care Resource Use Among Commercially Insured Non-Elderly Patients With Diabetic Macular EdemaOphthalmic Surgery, Lasers and Imaging Retina, 2015
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular EdemaNew England Journal of Medicine, 2015
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III TrialsOphthalmology, 2013
- Global Prevalence and Major Risk Factors of Diabetic RetinopathyDiabetes Care, 2012
- Diabetic macular edema: Current and emerging therapiesMiddle East African Journal of Ophthalmology, 2012
- Burden of illness of diabetic macular edema: literature reviewCurrent Medical Research and Opinion, 2010
- Diagnosed diabetic retinopathy in France, Italy, Spain, and the United KingdomPrimary Care Diabetes, 2007
- Diabetic Retinopathy in a Multi-ethnic Cohort in the United StatesAmerican Journal of Ophthalmology, 2006
- Prevalence of diabetic retinopathy in adult LatinosOphthalmology, 2004
- The Wisconsin Epidemiologic Study of Diabetic RetinopathyOphthalmology, 1989